Human antibodies that bind human il-12 and methods for producing
CA 2669512 A1 · Owner: White, Michael · Inventors: Banerjee, Subhashis; White, Michael; Derbyshire, Elaine J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Human antibodies, preferably recombinant human antibodies that specifically , bind to , human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 , and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a , full--length antibody or an antigen-binding portion thereof. The antibodies or antibody portions, of , the inveniton are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g. in a human , subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors , and host cells for expressing the recombinant human antibodies of the invention, and methods of , synthesizing …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 24, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 24, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 24, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.